Angelo Di Leo
- Oncology top 0.1%
- Cancer Research top 0.1%
- Pulmonary and Respiratory Medicine top 0.2%
- Molecular Biology top 1%
- Radiology, Nuclear Medicine and Imaging top 0.5%
- Co-authors
- Martine PiccartLaura BiganzoliDenis LarsimontGhizlane RouasGiuseppe VialeChristos SotiriouMarianne PaesmansLuca Malorni
- Topics
- HER2/EGFR in Cancer Research (119 papers)Breast Cancer Treatment Studies (108 papers)Cancer Treatment and Pharmacology (102 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaPLoS ONE
- Partner nations
- ItalyBelgiumUnited States
In The Last Decade
Angelo Di Leo
306 papers receiving 14.0k citations
Hit Papers
Peers
Comparison fields: 5 of 138
- Oncology 9.9k
- Cancer Research 5.2k
- Pulmonary and Respiratory Medicine 4.5k
- Molecular Biology 4.1k
- Radiology, Nuclear Medicine and Imaging 1.7k
Countries citing papers authored by Angelo Di Leo
This map shows the geographic impact of Angelo Di Leo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angelo Di Leo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angelo Di Leo more than expected).
Fields of papers citing papers by Angelo Di Leo
This network shows the impact of papers produced by Angelo Di Leo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angelo Di Leo. The network helps show where Angelo Di Leo may publish in the future.
Co-authorship network of co-authors of Angelo Di Leo
This figure shows the co-authorship network connecting the top 25 collaborators of Angelo Di Leo. A scholar is included among the top collaborators of Angelo Di Leo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angelo Di Leo. Angelo Di Leo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 8 | |
| 2 | 62 | |
| 3 | 37 | |
| 4 | 21 | |
| 5 | 5 | |
| 6 | 14 | |
| 7 | 16 | |
| 8 | Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014) | 5 |
| 9 | 20 | |
| 10 | 3 | |
| 11 | Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98breakdown → | 1213 |
| 12 | 345 | |
| 13 | 134 | |
| 14 | 55 | |
| 15 | Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with single-agent doxorubicin or single-agent docetaxel | 40 |
| 16 | HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. | 216 |
| 17 | HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. | 11 |
| 18 | Bcl-2 as a predictive marker for tamoxifen responsiveness in the adjuvant setting of node-positive breast cancer | 2 |
| 19 | Actualités thérapeutiques dans le cancer du sein | 1 |
| 20 | Docetaxel in the treatment of breast cancer: Current status, ongoing trials and future directions | 2 |
About Angelo Di Leo
Angelo Di Leo is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 313 papers that have together received 14.4k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (119 papers), Breast Cancer Treatment Studies (108 papers) and Cancer Treatment and Pharmacology (102 papers). The work is most often cited by research in Oncology (9.9k citations), Cancer Research (5.2k citations) and Pulmonary and Respiratory Medicine (4.5k citations). Angelo Di Leo has collaborated with scholars based in Italy, Belgium and United States. Frequent co-authors include Martine Piccart, Laura Biganzoli, Denis Larsimont, Ghizlane Rouas, Giuseppe Viale, Christos Sotiriou, Marianne Paesmans, Luca Malorni, Catherine Oakman and David Gancberg. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.